Optimapharm
ActiveSummary
Optimapharm has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €96,701 and a net result of €92,091. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 34% of 2,990 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
06-03
Gazette deed
Resignation: Martina Okun Šola (director)Appointment: Mirna Šenjug Novak (director) · Director discharge4 facts ▸
- General meeting, 23-11-2023
- Director resignation, Martina Okun Šola
- Director discharge, Martina Okun Šola
- Director appointment, Mirna Šenjug Novak (director)
About the unread acts
Of the 7 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 6 have not been read yet: what they contain is neither established nor disproved here.